Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quizartinib in Japanese patients with FLT3-ITD positive R/R AML
NCT02984995Phase 2Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Dec 2016
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of quizartinib in acute myeloid leukemia (AML) (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Composite Complete Remission Rate. Started Dec 2016; status: completed.
02
Drugs
quizartinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02984995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02984995.